Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Determining the Possible Role of Hepatocyte Growth Factor Receptor Splice Site Mutation as a Key Driver in Lung Adenocarcinoma

EF 2015-16

Résumé
It is known that the DNA in cancer cells contain key changes that drive tumour development, and that cancer cells often depend on these mutations for their continued growth and survival. Therefore, identification of such changes and targeting them with inhibitors offers a method of treating patients with a curative intent. Through assessing the DNA of human lung tumours, our lab has recently uncovered a new type of mutation in a gene known as MET which occurs in ~5% of all patients. We propose that this mutation stabilizes the product of the gene, leading to overactive cell growth and may provide a target for therapeutic intervention in patients with tumours containing this change. To test this, we have created a unique mouse model that expresses the mutant MET gene specifically in lung cells and will monitor these animals for tumour growth and survival to determine whether the mutation is sufficient for causing lung cancer. We will then assess the tumours that develop to determine how the MET mutation is causing the uncontrolled growth, which will inform how we can potentially inhibit this process. Lastly, we will test if suppression of these processes with drugs that inhibit MET - or other factors regulated by the mutation - in different ways can extend the survival and lead to cancer regression in mice with tumours driven by this change. If successful, these findings would suggest that lung cancer patients with MET mutant tumours are candidates for targeted therapy and should be screened for this purpose in the clinic. Since many such inhibitors are already clinically approved for other types of cancer, this work may rapidly facilitate the translation of the mutation from a basic finding to an avenue for therapeutic intervention in lung cancer patients.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
349899
Name
Lu Cheng-Hsiang
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Determining the Possible Role of Hepatocyte Growth Factor Receptor Splice Site Mutation as a Key Driver in Lung Adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Disease Progression; Driver Mutations; Histology; Immunohistochemistry; Oncogene Addiction; Signalling Pathways; Survival; Tetracycline-Inducible Transgenic System; Tyrosine Kinase Inhibitors; Tyrosine Kinase Receptors
Abstract
It is known that the DNA in cancer cells contain key changes that drive tumour development, and that cancer cells often depend on these mutations for their continued growth and survival. Therefore, identification of such changes and targeting them with inhibitors offers a method of treating patients with a curative intent. Through assessing the DNA of human lung tumours, our lab has recently uncovered a new type of mutation in a gene known as MET which occurs in ~5% of all patients. We propose that this mutation stabilizes the product of the gene, leading to overactive cell growth and may provide a target for therapeutic intervention in patients with tumours containing this change. To test this, we have created a unique mouse model that expresses the mutant MET gene specifically in lung cells and will monitor these animals for tumour growth and survival to determine whether the mutation is sufficient for causing lung cancer. We will then assess the tumours that develop to determine how the MET mutation is causing the uncontrolled growth, which will inform how we can potentially inhibit this process. Lastly, we will test if suppression of these processes with drugs that inhibit MET - or other factors regulated by the mutation - in different ways can extend the survival and lead to cancer regression in mice with tumours driven by this change. If successful, these findings would suggest that lung cancer patients with MET mutant tumours are candidates for targeted therapy and should be screened for this purpose in the clinic. Since many such inhibitors are already clinically approved for other types of cancer, this work may rapidly facilitate the translation of the mutation from a basic finding to an avenue for therapeutic intervention in lung cancer patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lu, Cheng-Hsiang
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~